- Home
- DSM vs ABEO Comparison
DSM vs ABEO Comparison
Compare DSM & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSM | ABEO |
|---|---|---|
| Founded | 1989 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 280.2M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | DSM | ABEO |
|---|---|---|
| Price | $6.01 | $4.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.75 |
| AVG Volume (30 Days) | 95.0K | ★ 1.4M |
| Earning Date | 01-01-0001 | 03-17-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | N/A | $112.53 |
| P/E Ratio | ★ N/A | $4.20 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $5.28 | $3.93 |
| 52 Week High | $6.30 | $7.54 |
Technical Indicators
Market Signals| Indicator | DSM | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 41.94 |
| Support Level | $5.89 | $4.00 |
| Resistance Level | $6.26 | $5.62 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 56.67 | 31.01 |
Price Performance
Historical ComparisonAbout DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.